Tissue sampling in lung cancer: a review in light of the MERIT experience.

[1]  Michael Thomas,et al.  Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  M. Ligtenberg,et al.  A Brief Retrospective Report on the Feasibility of Epidermal Growth Factor Receptor and KRAS Mutation Analysis in Transesophageal Ultrasound- and Endobronchial Ultrasound-Guided Fine Needle Cytological Aspirates , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  T. Wibmer,et al.  Cryoprobe biopsy increases the diagnostic yield in endobronchial tumor lesions. , 2010, The Journal of thoracic and cardiovascular surgery.

[4]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[5]  K. Kerr,et al.  Quantitative Analysis of Tumor in Bronchial Biopsy Specimens , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  P.-C. Yang,et al.  A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. Paz-Ares,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[8]  S. Thongprasert,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[9]  R. Herbst,et al.  Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. , 2009, Clinical lung cancer.

[10]  M. Tsao,et al.  Molecular predictive and prognostic markers in non-small-cell lung cancer. , 2009, The Lancet. Oncology.

[11]  D. Lacombe,et al.  Targeted therapies in the treatment of advanced/metastatic NSCLC. , 2009, European journal of cancer.

[12]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[13]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Susanna M Cramb,et al.  The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  S. Dacic.  EGFR Assays in Lung Cancer , 2008, Advances in anatomic pathology.

[16]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[17]  J. Soria,et al.  Gene expression profiling of non-small-cell lung cancer , 2008, Expert review of molecular diagnostics.

[18]  G. Giaccone,et al.  Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Bubendorf,et al.  Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers , 2007, British Journal of Cancer.

[20]  C. Watkins,et al.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[23]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[24]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Ko-pen Wang,et al.  Bronchoscopic Needle Aspiration of Mediastinal and Hilar Lymph Nodes , 1997 .

[27]  L. Davies,et al.  Cardiovascular consequences of fibreoptic bronchoscopy. , 1997, The European respiratory journal.

[28]  J. Varon,et al.  Complications from Flexible Bronchoscopy in a Training Program , 1996 .

[29]  G I Lukomsky,et al.  Complications of bronchoscopy: comparison of rigid bronchoscopy under general anesthesia and flexible fiberoptic bronchoscopy under topical anesthesia. , 1981, Chest.

[30]  G. Snider,et al.  A prospective cooperative study of complications following flexible fiberoptic bronchoscopy. , 1978, Chest.

[31]  R. Enck,et al.  Lung cancer: diagnosis and management. , 2007, American family physician.